Grace Therapeutics, Inc. Earnings Per Share (Basic)
Grace Therapeutics, Inc. (GRCE) reported Earnings Per Share (Basic) of -$0.91 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-13
- Grace Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.91.
- Grace Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.07, a 248.45% decline year-over-year.
- Grace Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.14.
- Grace Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.06.
- Grace Therapeutics, Inc. earnings per share, basic for fiscal 2026 was -$0.47.
- Grace Therapeutics, Inc. earnings per share, basic for fiscal 2025 was -$0.79.
- Grace Therapeutics, Inc. earnings per share, basic for fiscal 2024 was -$1.35.
- Grace Therapeutics, Inc. earnings per share, basic for fiscal 2023 was -$5.71.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.91 10-Q · filed 2026-08-13 | -$0.98 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.12 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.20 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2026-03-31 | -$0.07 derived: net income ÷ weighted average shares · filed 2026-07-28 | -$0.20 derived: net income ÷ weighted average shares · filed 2026-07-28 | -$0.27 derived: net income ÷ weighted average shares · filed 2026-07-28 | -$0.47 10-K · filed 2026-06-18 | ||||
| 2025-12-31 | -$0.14 10-Q · filed 2026-02-12 | -$0.20 derived: net income ÷ weighted average shares · filed 2026-02-12 | -$0.41 10-Q · filed 2026-02-12 | -$0.38 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-09-30 | -$0.06 10-Q · filed 2025-11-13 | -$0.27 10-Q · filed 2025-11-13 | -$0.24 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.55 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-06-30 | -$0.21 10-Q · filed 2026-08-13 | -$0.18 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.50 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.78 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-03-31 | $0.05 derived: net income ÷ weighted average shares · filed 2026-07-28 | -$0.28 derived: net income ÷ weighted average shares · filed 2026-07-28 | -$0.57 derived: net income ÷ weighted average shares · filed 2026-07-28 | -$0.79 10-K · filed 2026-06-18 | ||||
| 2024-12-31 | -$0.36 10-Q · filed 2026-02-12 | -$0.66 derived: net income ÷ weighted average shares · filed 2026-02-12 | -$0.89 10-Q · filed 2026-02-12 | -$1.18 derived: net income ÷ weighted average shares · filed 2026-07-28 | ||||
| 2024-09-30 | -$0.30 10-Q · filed 2025-11-13 | -$0.53 10-Q · filed 2025-11-13 | -$0.81 derived: net income ÷ weighted average shares · filed 2026-07-28 | -$1.02 derived: net income ÷ weighted average shares · filed 2026-07-28 | ||||
| 2024-06-30 | -$0.24 10-Q · filed 2025-08-12 | -$0.52 derived: net income ÷ weighted average shares · filed 2026-07-28 | -$0.72 derived: net income ÷ weighted average shares · filed 2026-07-28 | -$1.10 derived: net income ÷ weighted average shares · filed 2026-07-28 | ||||
| 2024-03-31 | -$0.28 derived: net income ÷ weighted average shares · filed 2026-07-28 | -$0.48 derived: net income ÷ weighted average shares · filed 2026-07-28 | -$0.87 derived: net income ÷ weighted average shares · filed 2026-07-28 | -$1.35 10-K · filed 2025-06-23 | ||||
| 2023-12-31 | -$0.21 10-Q · filed 2025-02-13 | -$0.59 derived: net income ÷ weighted average shares · filed 2025-02-13 | -$1.09 10-Q · filed 2025-02-13 | -$4.56 derived: net income ÷ weighted average shares · filed 2025-02-13 | ||||
| 2023-09-30 | -$0.43 10-Q · filed 2024-11-13 | -$0.97 10-Q · filed 2024-11-13 | -$4.86 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$5.38 derived: net income ÷ weighted average shares · filed 2024-11-13 | ||||
| 2023-06-30 | -$0.54 10-Q · filed 2024-08-09 | -$4.44 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$4.96 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$5.63 derived: net income ÷ weighted average shares · filed 2024-11-13 | ||||
| 2023-03-31 | -$3.88 derived: net income ÷ weighted average shares · filed 2024-06-21 | -$4.42 derived: net income ÷ weighted average shares · filed 2024-06-21 | -$5.09 derived: net income ÷ weighted average shares · filed 2024-06-21 | -$5.71 10-K · filed 2024-06-21 | -$0.95 10-K · filed 2023-06-23 | |||
| 2022-12-31 | -$0.52 10-Q · filed 2024-02-12 | -$0.09 10-Q · filed 2023-02-14 | -$1.19 derived: net income ÷ weighted average shares · filed 2024-02-12 | -$1.80 10-Q · filed 2024-02-12 | -$0.30 10-Q · filed 2023-02-14 | -$0.75 derived: net income ÷ weighted average shares · filed 2024-02-12 | ||
| 2022-09-30 | -$0.66 10-Q · filed 2023-11-13 | -$0.11 10-Q · filed 2022-11-14 | -$1.28 10-Q · filed 2023-11-13 | -$0.21 10-Q · filed 2022-11-14 | -$0.47 derived: net income ÷ weighted average shares · filed 2024-02-12 | -$0.53 derived: net income ÷ weighted average shares · filed 2024-02-12 | ||
| 2022-06-30 | -$0.61 10-Q · filed 2023-08-11 | -$0.10 10-Q · filed 2022-08-11 | -$0.22 derived: net income ÷ weighted average shares · filed 2024-02-12 | -$0.30 derived: net income ÷ weighted average shares · filed 2024-02-12 | -$0.29 derived: net income ÷ weighted average shares · filed 2024-02-12 | |||
| 2022-03-31 | -$0.06 derived: net income ÷ weighted average shares · filed 2023-06-23 | -$0.13 derived: net income ÷ weighted average shares · filed 2023-06-23 | -$0.14 derived: net income ÷ weighted average shares · filed 2023-06-23 | -$0.27 10-K · filed 2023-06-23 | ||||
| 2021-12-31 | -$0.09 10-Q · filed 2023-02-14 | -$0.07 derived: net income ÷ weighted average shares · filed 2023-02-14 | -$0.23 10-Q · filed 2023-02-14 | |||||
| 2021-09-30 | -$0.03 10-Q · filed 2022-11-14 | -$0.07 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | -$0.12 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |